2 terminated. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Terminated 2 |
| Phase 1 | 1 | Terminated 1 |
Follow CD22 Positive: new trials by email Literature Review of CD22 Positive trials Research Report on CD22 Positive
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| ADCT-602 in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia ADCT-602 - Blasts 5 Percent or More of Bone Marrow Nucleated Cells, CD22 Positive | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 37 | 2018-08-24 | 2025-12-12 |
| Inotuzumab Ozogamicin in Treating Patients With Relapsed or Refractory CD22 Positive Acute Lymphoblastic Leukemia Inotuzumab Ozogamicin - CD22 Positive, Recurrent Acute Lymphoblastic Leukemia | Phase 2 | Terminated | M.D. Anderson Cancer Center | 4 | 2017-11-30 | 2021-04-12 |
Burkitt Lymphoma (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1)
Hemic and Lymphatic Diseases (2) · Immune System Diseases (2) · Immunoproliferative Disorders (2) · Lymphatic Diseases (2) · Lymphoproliferative Disorders (2) · Neoplasms (2) · Neoplasms by Histologic Type (2) · DNA Virus Infections (1) · Epstein-Barr Virus Infections (1) · Hematologic Diseases (1) · Herpesviridae Infections (1) · Infections (1) · Leukemia (1) · Leukemia, Lymphoid (1) · Lymphoma (1)
M.D. Anderson Cancer Center (2)
United States (2)
Elias Jabbour (1) · Nitin Jain (1)
P30CA016672 (1)